Robinson, Anthony M.
Rathore, Richa http://orcid.org/0000-0003-3708-8758
Redlich, Nathan J.
Adkins, Douglas R.
VanArsdale, Todd
Van Tine, Brian A.
Michel, Loren S.
Funding for this research was provided by:
Pfizer (000000, 000000, 00000)
Article History
Received: 27 January 2019
Revised: 24 October 2019
Accepted: 28 October 2019
First Online: 14 November 2019
Conflict of interest
: A.M.R., R.R., N.J.R. and L.S.M. report no conflicts of interest. B.A.V.T. reports Basic Science Grant Funding from Pfizer relating to this work; a 1-year grant from Polaris, Inc. in 2014; Basic Science Grant Funding from Pfizer, Tracon and Merck; consulting fees from Epizyme, Lilly, CytRX, Janssen, Immune Design, Daiichi Sankyo, Plexxicon, and Adaptimmune,; and speaking fees from Caris, Janseen, and Lilly outside the submitted work. D.R.A. reports Consultant/Advisory Board at Merck, Pfizer, Celgene, Eli Lilly; Research Funding from Merck, Pfizer, Celgene, Astra Zeneca, Atara, BluePrint Medicine, Cellceutix, Celldex, Novartis, Enzychem, Gliknik, BMS, Kura, Medimmune, Exelixis, Matrix Biomed, Innate Pharma, and Eli Lilly. T.V. is an employee of Pfizer and holds stock in Pfizer.